Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age

STATUS

Recruiting
participants needed

13320
sponsor

Sanofi Pasteur, a Sanofi Company

Send

Updated on 19 February 2024

See if I qualify

vaccination

influenza

hemagglutination inhibition

quadrivalent inactivated influenza vaccine

flu symptoms

Summary

The primary objective of the study is to compare the clinical efficacy of high-dose quadrivalent influenza vaccine (QIV-HD) to standard-dose quadrivalent influenza vaccine (QIV-SD) in participants 6 months through 35 months of age for the prevention of laboratory-confirmed influenza illness caused by any influenza A or B type.

The secondary objectives of the study are:

To compare QIV-HD to QIV-SD:
in participants 6 months through 35 months of age for the prevention of laboratory-confirmed influenza illness caused by any influenza A or B type using a more stringent threshold
in participants 6 months through 35 months of age for the prevention of laboratory-confirmed protocol-defined influenza-like illness caused by viral strains similar to those contained in the vaccine.
in participants 6 months through 23 months of age for the prevention of laboratory-confirmed influenza illness caused by any influenza A or B types.
To compare hemagglutination inhibition (HAI) immune response of QIV-HD to QIV-SD in participants 6 months through 35 months of age
To describe the HAI, seroneutralization (SN), and anti-neuraminidase (NA) immune response
To describe the immune response to revaccination in Season 3 (Northern Hemisphere)
To describe the safety profile of each vaccine

Description

The study is planned to start in the second half of 2020 with the Sentinel Safety Cohort. Following the Sentinel Safety Cohort, the main efficacy cohort will be conducted during the 2021-2022 Northern Hemisphere influenza season (Season 1), the 2021-2022 Southern Hemisphere influenza season (Season 2), and the 2021-2022-2023 Northern Hemisphere influenza season (Season 3).

Participants will receive either 1 or 2 doses of the study vaccine depending on whether they were previously influenza vaccinated or previously influenza unvaccinated, respectively.

Study duration per participant is approximately 6 to 7 months.

Details

Condition	Influenza Vaccine, Influenza, Influenza
Age	1-1 years
Treatment	Quadrivalent influenza vaccine, high-dose, Quadrivalent influenza vaccine, standard dose
Clinical Study Identifier	NCT04544267
Sponsor	Sanofi Pasteur, a Sanofi Company
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Aged 6 to 35 months on the day of the first study visit
	Informed consent form has been signed and dated by the parent(s) or guardian(s) and by an independent witness, if required by local regulations
	Participant and parent / guardian are able to attend all scheduled visits and to comply with all study procedures
	Covered by health insurance if required by local regulations
	For Season 3 Re-vaccination Cohort: eligible participants must have been enrolled in the Season 1 (2021-2022 Northern Hemisphere season) immunogenicity subset and must have completed all study procedures (ie, blood draws and vaccinations) in Season 1
Exclusion Criteria
	Participation at the time of study enrollment (or in the 4 weeks preceding the first study vaccination) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure
	For all participants: Receipt of any vaccine in the 30 days preceding the first study vaccination. For participants in immunogenicity subset: Planned receipt of any vaccine before Visit 2 for participants receiving 1 dose of influenza vaccine or Visit 3 for participants receiving 2 doses of influenza vaccine
	Previous vaccination against influenza in the preceding 6 months with either the study vaccine or another influenza vaccine
	Receipt of immune globulins, blood or blood-derived products in the past 3 months
	Known or suspected congenital or acquired immunodeficiency (eg, HIV); or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
	Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the study or to a vaccine containing any of the same substances. Exception: participants with an egg allergy are allowed to enroll in the study
	Thrombocytopenia, bleeding disorder, or receipt of anticoagulants that based on Investigator's judgment contraindicate intramuscular vaccination
	Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
	Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature 38.0 C [ 100.4 F]). A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided
	Identified as natural or adopted child of the Investigator or employee with direct involvement in the proposed study
	Personal or family history of Guillain-Barre Syndrome
	Any condition that in the opinion of the Investigator would pose a health risk to the participant if enrolled or could interfere with the evaluation of the vaccine
	Personal history of clinically significant development delay (at the discretion of the Investigator), neurologic disorder, or seizure disorder
	For Season 3 (2022-2023 Northern Hemisphere) main cohort: participants who were enrolled in a previous study season are excluded from Season 3, with the exception of the Re-vaccination Cohort
	The above information is not intended to contain all considerations relevant
	to a patient's potential participation in a clinical trial

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

vaccination

influenza

hemagglutination inhibition

quadrivalent inactivated influenza vaccine

flu symptoms

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age